Current status and prospects of long-term albumin treatment in patients with cirrhotic ascites

Yu TIAN; Jia HONG; Bingqiong WANG; Hong YOU

doi:10.3969/j.issn.1001-5256.2021.01.037

Volume 37 Issue 1

Jan. 2021

Turn off MathJax

Article Contents

Article Navigation > Journal of Clinical Hepatology > 2021 > 37(1): 173-175

PDF( 2020 KB)

Current status and prospects of long-term albumin treatment in patients with cirrhotic ascites

DOI: 10.3969/j.issn.1001-5256.2021.01.037

Liver Research Center, Beijing Friendship Hospital, Capital Medical University; National Clinical Research Center for Digestive Diseases, Beijing 100050, China

Received Date: 2020-07-03
Accepted Date: 2020-07-28
Published Date: 2021-01-20

Abstract

Abstract

At present, albumin is mainly used to prevent post-paracentesis circulatory dysfunction in patients with cirrhotic ascites, prevent renal dysfunction in patients with spontaneous peritonitis, and treat hepatorenal syndrome. Recent studies have shown that long-term albumin treatment can reduce the incidence rate of complications and improve overall prognosis in patients with cirrhotic ascites, which brings new insights into the indication for clinical application of albumin. This article reviews the clinical studies on the long-term administration of albumin in patients with cirrhotic ascites, aiming to provide evidence-based advice for further clinical research on long-term application of albumin in China.
- Liver Cirrhosis,
- Ascites,
- Serum Albumin

FullText(HTML)

References(24)

References

[1]	CARACENI P, RIGGIO O, ANGELI P, et al. Long-term albumin administration in decompensated cirrhosis (ANSWER): An open-label randomised trial[J]. Lancet, 2018, 391(10138): 2417-2429. DOI: 10.1016/S0140-6736(18)30840-7
[2]	di PASCOLI M, FASOLATO S, PIANO S, et al. Long-term administration of human albumin improves survival in patients with cirrhosis and refractory ascites[J]. Liver Int, 2019, 39(1): 98-105. DOI: 10.1111/liv.13968
[3]	ANGELI P, BERNARDI M, VILLANUEVA C, et al. EASL clinical practice guidelines for the management of patients with decompensated cirrhosis[J]. J Hepatol, 2018, 69(2): 406-460. DOI: 10.1016/j.jhep.2018.03.024
[4]	Chinese Society of Hepatology, Chinese Medical Association. Chinese guidelines on the management of liver cirrhosis[J]. J Clin Hepatol, 2019, 35(11): 2408-2425. (in Chinese) DOI: 10.3969/j.issn.1001-5256.2019.11.006 中华医学会肝病学分会. 肝硬化诊治指南[J]. 临床肝胆病杂志, 2019, 35(11): 2408-2425. DOI: 10.3969/j.issn.1001-5256.2019.11.006
[5]	CARACENI P, ANGELI P, PRATI D, et al. AISF-SIMTI position paper: The appropriate use of albumin in patients with liver cirrhosis[J]. Blood Transfus, 2016, 14(1): 8-22. http://europepmc.org/abstract/PMC/PMC4731339;jsessionid=pt8jgEa27FCZKCJW0WgK.0
[6]	BERNARDI M, MOREAU R, ANGELI P, et al. Mechanisms of decompensation and organ failure in cirrhosis: From peripheral arterial vasodilation to systemic inflammation hypothesis[J]. J Hepatol, 2015, 63(5): 1272-1284. DOI: 10.1016/j.jhep.2015.07.004
[7]	BERNARDI M, CARACENI P. Novel perspectives in the management of decompensated cirrhosis[J]. Nat Rev Gastroenterol Hepatol, 2018, 15(12): 753-764. DOI: 10.1038/s41575-018-0045-2
[8]	GENTILINI P, CASINI-RAGGI V, DI FIORE G, et al. Albumin improves the response to diuretics in patients with cirrhosis and ascites: Results of a randomized, controlled trial[J]. J Hepatol, 1999, 30(4): 639-645. DOI: 10.1016/S0168-8278(99)80194-9
[9]	ROMANELLI RG, LA VILLA G, BARLETTA G, et al. Long-term albumin infusion improves survival in patients with cirrhosis and ascites: An unblinded randomized trial[J]. World J Gastroenterol, 2006, 12(9): 1403-1407. DOI: 10.3748/wjg.v12.i9.1403
[10]	GARCIA-TSAO G. Long-term albumin in cirrhosis: Is it the ANSWER?[J]. Lancet, 2018, 391(10138): 2391-2392. DOI: 10.1016/S0140-6736(18)30948-6
[11]	BORTOLUZZI A, CEOLOTTO G, GOLA E, et al. Positive cardiac inotropic effect of albumin infusion in rodents with cirrhosis and ascites: Molecular mechanisms[J]. Hepatology, 2013, 57(1): 266-276. DOI: 10.1002/hep.26021
[12]	FERNÁNDEZ J, MONTEAGUDO J, BARGALLO X, et al. A randomized unblinded pilot study comparing albumin versus hydroxyethyl starch in spontaneous bacterial peritonitis[J]. Hepatology, 2005, 42(3): 627-634. DOI: 10.1002/hep.20829
[13]	O'BRIEN AJ, FULLERTON JN, MASSEY KA, et al. Immunosuppression in acutely decompensated cirrhosis is mediated by prostaglandin E2[J]. Nat Med, 2014, 20(5): 518-523. DOI: 10.1038/nm.3516
[14]	FERNÁNDEZ J, CLÀRIA J, AMORÓS A, et al. Effects of albumin treatment on systemic and portal hemodynamics and systemic inflammation in patients with decompensated cirrhosis[J]. Gastroenterology, 2019, 157(1): 149-162. DOI: 10.1053/j.gastro.2019.03.021
[15]	JVRGENS G, MVLLER M, GARIDEL P, et al. Investigation into the interaction of recombinant human serum albumin with re-lipopolysaccharide and lipid A[J]. J Endotoxin Res, 2002, 8(2): 115-126. DOI: 10.1177/09680519020080020501
[16]	DAVID SA, BALARAM P, MATHAN VI. Characterization of the interaction of lipid A and lipopolysaccharide with human serum albumin: Implications for an endotoxin carrier function for albumin[J]. Innate Immunity, 1995, 2(2): 99-106. http://ini.sagepub.com/content/2/2/99.abstract
[17]	FUKUI H. Relation of endotoxin, endotoxin binding proteins and macrophages to severe alcoholic liver injury and multiple organ failure[J]. Alcohol Clin Exp Res, 2005, 29(11 Suppl): 172S-179S. http://europepmc.org/abstract/MED/16344605
[18]	DZIARSKI R. Cell-bound albumin is the 70-kDa peptidoglycan-, lipopolysaccharide-, and lipoteichoic acid-binding protein on lymphocytes and macrophages[J]. J Biol Chem, 1994, 269(32): 20431-20436. http://www.ncbi.nlm.nih.gov/pubmed/8051139?dopt=Abstract
[19]	SOLÀ E, SOLÉ C, SIMÓN-TALERO M, et al. Midodrine and albumin for prevention of complications in patients with cirrhosis awaiting liver transplantation. A randomized placebo-controlled trial[J]. J Hepatol, 2018, 69(6): 1250-1259. DOI: 10.1016/j.jhep.2018.08.006
[20]	BERNARDI M, ANGELI P, CLARIA J, et al. Albumin in decompensated cirrhosis: New concepts and perspectives[J]. Gut, 2020, 69(6): 1127-1138. DOI: 10.1136/gutjnl-2019-318843
[21]	EVANS TW. Review article: Albumin as a drug—biological effects of albumin unrelated to oncotic pressure[J]. Aliment Pharmacol Ther, 2002, 16(Suppl) 5: 6-11.
[22]	GARCIA-MARTINEZ R, CARACENI P, BERNARDI M, et al. Albumin: Pathophysiologic basis of its role in the treatment of cirrhosis and its complications[J]. Hepatology, 2013, 58(5): 1836-1846. DOI: 10.1002/hep.26338
[23]	CARACENI P, RIGGIO O, ANGELI P, et al. Serum albumin concentration as guide for long-term albumin treatment in patients with cirrhosis and uncomplicated ascites: Lessons from the ANSWER study[J]. J Hepatol, 2019, 70(1): e53. http://www.sciencedirect.com/science/article/pii/S0618827819300957
[24]	LI HB, MEN P, WANG Y, et al. Experts consensus on rapid advice guidelines for the pharmacological management of human albumin in patients with liver cirrhosis[J]. J Clin Med, 2018, 16(12): 10-16. (in Chinese) https://www.cnki.com.cn/Article/CJFDTOTAL-LCYW201812003.htm 李慧博, 门鹏, 王宇, 等. 《人血白蛋白用于肝硬化治疗的快速建议指南》解读[J]. 临床药物治疗杂志, 2018, 16(12): 10-16. https://www.cnki.com.cn/Article/CJFDTOTAL-LCYW201812003.htm

Relative Articles

Supplements(0)

Cited By

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (1264) PDF downloads(133)

Current status and prospects of long-term albumin treatment in patients with cirrhotic ascites

DOI: 10.3969/j.issn.1001-5256.2021.01.037

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Current status and prospects of long-term albumin treatment in patients with cirrhotic ascites

DOI: 10.3969/j.issn.1001-5256.2021.01.037

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

About Journal

Submission Guideline

Journal Online

Hepatobiliary College

Guidelines

Export File

Citation

Format

Content